Alpha-methyl CoA racemase expression in renal cell carcinomas

Molinié, Vincent; Balaton, A.; Rotman, Samuel; Mansouri, Douha; Pinieux, I. De; Homsi, T.; Guillou, Louis

doi:10.1016/j.humpath.2006.01.012

Cited by 66 publications

(48 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is interesting that these markers are not present in all glomerules and PeC. The glomerular PeC staining characteristics have not been emphasized in other publications (4,8,14,30). We sometimes see that PTC line Bowman's space and take the place of PeC in kidney needle biopsies performed for various reasons.…”

Section: Dıscussıonmentioning

confidence: 86%

See 1 more Smart Citation

Immunohistochemical markers in renal tumors and findings in non-tumoral renal parenchyma

Şen

Sarsık

Şimşir³

2010

TJPATH

View full text Add to dashboard Cite

Objective: Renal epithelial cells comprise distinct pathological and physiological differences. Renal epithelial neoplasms derived from these cells may show overlapping morphological features, and differential diagnosis requiring the use of ancillary methods. The purpose of this study was to determine the diagnostic utility of the immunohistochemical expression patterns of a wide range of markers in renal epithelial cells. Material and Method:Normal renal cortical parenchyma and renal pelvis were immunostained for cytokeratin (CK) subtypes (CK7, CK19, CK34βe12), vimentin, RCCMa, CD10, CD117, AMACR, WT-1, eMA and p63. The immunohistochemical expression patterns were examined in 10 cases.

show abstract

Section: Dıscussıonmentioning

confidence: 86%

“…eMA has been reported negative at times in metanephric adenoma (47). However, although RCCpap and MTSCC originate distally, they show a high rate of AMACR positivity, normally demonstrated at the proximal tubule (9,30). This may indicate aberrant expression in tumors originating from the distal nephron.…”

Section: Dıscussıonmentioning

confidence: 98%

Immunohistochemical markers in renal tumors and findings in non-tumoral renal parenchyma

Şen

Sarsık

Şimşir³

2010

TJPATH

View full text Add to dashboard Cite

show abstract

“…38 Almost all papillary RCCs are positive for AMACR, but other types of RCCs are rarely positive. [39][40][41] TFE3, TFEB, and Cathepsin-K TFE3 is a transcription factor that is overexpressed in a group of RCCs with translocation involving Xp11.2. Positive nuclear labeling for TFE3 by immunohistochemistry is a sensitive and specific marker for Xp11.2 translocation RCC, which occurs primarily in children and young adults.…”

Section: Parvalbumin Claudin 7 and 8 And Cd117mentioning

confidence: 99%

Role of Immunohistochemistry in Diagnosing Renal Neoplasms: When Is It Really Useful?

Shen

Truong²,

Scarpelli

et al. 2012

Archives of Pathology &Amp; Laboratory Medicine

104

100

View full text Add to dashboard Cite

Context.—With the refinement of molecular and histologic classifications of renal neoplasms and the availability of more-effective molecular targeted therapy for specific renal neoplasms, immunohistochemical techniques will play an increasingly important role in the diagnosis of renal neoplasm. During the past few decades, many markers have been evaluated for their role in the diagnosis, prognosis, and prediction of treatment for renal neoplasms. The number of useful markers in our routine practice continues to increase. The challenge will be to choose among them and to decide in which situations immunohistochemistry will be truly useful. Objectives.—To review the diagnostic utility of molecular markers for renal neoplasms and common diagnostic scenarios that call for immunohistochemistry in routine practice. Data Sources.—This review is based on published literature and personal experience. Conclusions.—Some of the most important and useful markers for the diagnosis of renal neoplasm include cytokeratins, vimentin, PAX2, PAX8, RCC marker, CD10, E-cadherin, kidney-specific cadherin, parvalbumin, claudin-7, claudin-8, α-methylacyl coenzyme A racemase, CD117, TFE3, thrombomodulin, uroplakin III, p63, CD57, and carbonic anhydrase IX. Each marker has its diagnostic role in a specific diagnostic setting. The common diagnostic situations that call for immunohistochemical staining are differential diagnoses of renal versus nonrenal neoplasms, histologic subtyping of renal cell carcinoma, diagnosis of rare primary renal neoplasms, diagnosis of renal neoplasms in small core-biopsy specimens, diagnosis of possible metastatic renal carcinomas, and less frequently, molecular prognostication.

show abstract

“…AMACR staining is often negative in CCRCC but it can be focally or, rarely, diffusely positive in CCRCC. 39,63,69 For this particular differential diagnosis, a panel including AMACR, CA9, and cytokeratin 7 (CK7) is quite useful. While CK7 staining has been described in CCRCC, this is an uncommon finding; staining is usually patchy and centered around cystic areas within a tumor.…”

mentioning

confidence: 99%

Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine

Goyal

Gersbach

Yang

et al. 2013

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—The World Health Organization classification of renal tumors synthesizes morphologic, immunohistochemical, and molecular findings to define more than 40 tumor types. Of these, clear cell (conventional) renal cell carcinoma is the most common malignant tumor in adults and—with the exception of some rare tumors—the most deadly. The diagnosis of clear cell renal cell carcinoma on morphologic grounds alone is generally straightforward, but challenging cases are not infrequent. A misdiagnosis of clear cell renal cell carcinoma has clinical consequences, particularly in the current era of targeted therapies. Objective.—To highlight morphologic mimics of clear cell renal cell carcinoma and provide strategies to help differentiate clear cell renal cell carcinoma from other renal tumors and lesions. The role of the pathologist in guiding treatment for renal malignancies will be emphasized to stress the importance of proper tumor classification in patient management. Data Sources.—Published literature and personal experience. Conclusions.—In challenging cases, submission of additional tissue is often an inexpensive and effective way to facilitate a correct diagnosis. If immunohistochemical stains are to be used, it is best to use a panel of markers, as no one marker is specific for a given renal tumor subtype. Selection of limited markers, based on a specific differential diagnosis, can be as useful as a large panel in reaching a definitive diagnosis. For renal tumors, both the presence and absence of immunoreactivity and the pattern of labeling (membranous, cytoplasmic, diffuse, focal) are important when interpreting the results of immunohistochemical stains.

show abstract

Alpha-methyl CoA racemase expression in renal cell carcinomas

Cited by 66 publications

References 35 publications

Immunohistochemical markers in renal tumors and findings in non-tumoral renal parenchyma

Immunohistochemical markers in renal tumors and findings in non-tumoral renal parenchyma

Role of Immunohistochemistry in Diagnosing Renal Neoplasms: When Is It Really Useful?

Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine

Contact Info

Product

Resources

About